Zobrazeno 1 - 10
of 103
pro vyhledávání: '"Ignacio Bernabeu"'
Autor:
Miguel Chenlo, Iria A. Rodriguez-Gomez, Ramon Serramito, Angela R. Garcia-Rendueles, Rocío Villar-Taibo, Eva Fernandez-Rodriguez, Sihara Perez-Romero, Maria Suarez-Fariña, Alfredo Garcia-Allut, Jose M. Cabezas-Agricola, Javier Rodriguez-Garcia, Pamela V. Lear, Rosa M. Alvarez-San Martin, Cristina Alvarez-Escola, Ignacio Bernabeu, Clara V. Alvarez
Publikováno v:
EBioMedicine, Vol 43, Iss , Pp 537-552 (2019)
Background: Acromegaly is produced by excess growth hormone secreted by a pituitary adenoma of somatotroph cells (ACRO). First-line therapy, surgery and adjuvant therapy with somatostatin analogs, fails in 25% of patients. There is no predictive fact
Externí odkaz:
https://doaj.org/article/18978d90c30642d6a6cfc6c540bef848
Autor:
Joan Gil, Montserrat Marques-Pamies, Elena Valassi, Araceli García-Martínez, Guillermo Serra, Cristina Hostalot, Carmen Fajardo-Montañana, Cristina Carrato, Ignacio Bernabeu, Mónica Marazuela, Helena Rodríguez-Lloveras, Rosa Cámara, Isabel Salinas, Cristina Lamas, Betina Biagetti, Andreu Simó-Servat, Susan M. Webb, Antonio Picó, Mireia Jordà, Manel Puig-Domingo
Publikováno v:
Biomedicines, Vol 10, Iss 2, p 460 (2022)
Acromegaly is caused by excess growth hormone (GH) produced by a pituitary tumor. First-generation somatostatin receptor ligands (SRLs) are the first-line treatment. Several studies have linked E-cadherin loss and epithelial-mesenchymal transition (E
Externí odkaz:
https://doaj.org/article/4eaadb6f99aa4534893da681de8f25c9
Autor:
Alberto Pradilla Dieste, Miguel Chenlo, Sihara Perez-Romero, Ángela R. Garcia-Rendueles, Maria Suarez-Fariña, Montserrat Garcia-Lavandeira, Ignacio Bernabeu, José Manuel Cameselle-Teijeiro, Clara V. Alvarez
Publikováno v:
Frontiers in Endocrinology, Vol 11 (2020)
The RET tyrosine kinase receptor is expressed by the endocrine somatotroph cells of the pituitary where it has important functions regulating survival/apoptosis. However, RET is also expressed by the GPS pituitary stem cells localized in a niche betw
Externí odkaz:
https://doaj.org/article/92655aad3eed43f5861cf1d9ce84b6d4
Autor:
Maria Susana Mallea-Gil, Ignacio Bernabeu, Adriana Spiraquis, Alejandra Avangina, Lourdes Loidi, Carolina Ballarino
Publikováno v:
Case Reports in Endocrinology, Vol 2016 (2016)
Pegvisomant (PEGv) is a growth hormone receptor antagonist approved for the treatment of acromegaly; one of its documented adverse effects is reversible elevation of hepatic enzymes. We report a 39-year-old male acromegalic patient with a pituitary m
Externí odkaz:
https://doaj.org/article/0077c11b4c2f47179bbf11ad7ee7a456
Autor:
Manel Puig-Domingo, Montserrat Marques-Pamies, Joan Gil, Elena Valassi, Olga Gimenez-Palop, Marta Hernandez, Rocio Villar Taibo, Betina Biagetti, Gemma Xifra Villarroya, Andreu Simo-Servat, Roxana Zavala, Inmaculada Simon, Marta Araujo-Castro, Rogelio Garcia Centeno, Maria Calatayud, Federico Vazquez San Miguel, N Vilarrasa, Isabel Salinas Vert, Mireia Mora, Felicia Alexandra Hanzu, Maria Paz De Miguel Novoa, Isabel Pavon, Concepcion Blanco, Cristina Alvarez-Escola, Miguel Antonio Sampedro-Nunez, Mireia Jorda, Ignacio Bernabeu, Susan Webb, Monica Marazuela
Publikováno v:
Endocrine Abstracts.
Autor:
Montserrat Marques-Pamies, Joan Gil, Mireia Jorda, Elena Valassi, Betina Biagetti, Marta Hernandez, Olga Gimenez-Palop, Silvia Martinez, Cristina Carrato, Taibo Rocio Villar, Marta Araujo-Castro, Concepcion Blanco, Inmaculada Simon, Andreu Simo-Servat, Villarroya Gemma Xifra, San Miguel Federico Vazquez, Isabel Pavon, Centeno Rogelio Garcia, Roxana Zavala, Hanzu Felicia Alexandra, Mireia Mora, Maso Ana Aulinas, N Vilarrasa, Librizzi Maria Soledad, De Miguel Novoa Maria Paz, Cristina Alvarez-Escola, Antonio Pico-Alfonso, Sampedro-Nunez Miguel Antonio, Vert Isabel Salinas, Carmen Fajardo-Montanana, Rosa Camara-Gomez, Ignacio Bernabeu, Susan Webb, Monica Marazuela, Manel Puig-Domingo
Publikováno v:
Endocrine Abstracts.
Autor:
Betina Biagetti, Pedro Iglesias, Taibo Rocio Villar, Moure Maria Dolores, Fano Miguel Paja, Castro Marta Araujo, Blanco Jessica Ares, Alvarez Escola Maria Cristina, Almudena Vicente, Guivernau Elia Alvarez, Iria Novoa-Testa, Carballido Fernando Cordido, Rosa Camara-Gomez, Beatriz Lecumberri, Gomez Carlos Garcia, Ignacio Bernabeu, Miguelez Laura Manjon, Sonia Gaztambide, Susan Webb, Menendez Torre Edelmiro Luis, Diez Juan Jose, Canonge Rafael Simo, Manel Puig-Domingo
Publikováno v:
Endocrine Abstracts.
Autor:
Miguel Sampedro-Núñez, Edelmiro Menendez, Ignacio Bernabeu, Marcos Díaz-Muñoz, M. Luz Samaniego, Laura Sánchez-Cenizo, Rocío Villar, Mónica Marazuela, Concepción Blanco, Miguel Paja
Publikováno v:
Endocrine. 75:525-536
Objectives To evaluate disease activity status using the Acromegaly Disease Activity Tool (ACRODAT®) in a cohort of Spanish acromegaly patients, to assess the relationship between the level of disease activity according to both ACRODAT® and the phy
Autor:
Sabina Ruiz, Moreno Eva Venegas, Joan Gil, ROSA CAMARA, Betina Biagetti, Galvez Moreno Maria Angeles, Silvia Maraver, Inmaculada Gonzalez-Molero, Antonio Pico-Alfonso, Galiana Pablo Abellan, pablo trincado, Herrera Arranz Maria Teresa, Pilar Olvera, Villarroya Gemma Xifra, Ignacio Bernabeu, Mira Sharona Azriel, Lourdes Garcia-GarciA-Doncel, Mireia Jorda, Elena Valassi, Manel Puig-Domingo
Publikováno v:
Endocrine Abstracts.
Autor:
Carlos del Pozo, Gabriel Obiols, Raquel Buj, Laura Pons, Joan Gil, Isabel Salinas, Alberto Blanco, Carmen Fajardo-Montañana, Montserrat Marques-Pamies, Miguel Sampedro-Núñez, Susan M. Webb, Manel Puig-Domingo, Mónica Marazuela, Clara V. Alvarez, Guillermo Serra, Antonio Picó, Rosa Cámara, Carles Villabona, Ignacio Bernabeu, Elena Valassi, Mireia Jordà, Cristina Carrato, Araceli García-Martínez
Publikováno v:
Endocrine-Related Cancer
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Pharmacologic treatment of acromegaly is currently based upon assay-error strategy, the first-generation somatostatin receptor ligands (SRL) being the first-line treatment. However, about 50% of patients do not respond adequately to SRL. Our objectiv